Between 2022 and 2024, the FDA declared semaglutide (the active ingredient in Ozempic and Wegovy) to be in national shortage. During that period, 503A and 503B compounding pharmacies were legally allowed to produce compounded semaglutide as an alternative to the branded product. A parallel telehealth industry sprang up to prescribe and ship compounded semaglutide directly to consumers, often at $150-$400 per month — a fraction of the roughly $1,300/month Novo Nordisk retail price.
In late 2024 and early 2025, the FDA declared the shortage resolved. The legal basis for widespread compounding evaporated. The enforcement is now catching up to the market. This is one of the fastest-moving regulatory situations in pharmaceuticals right now, and understanding it matters if you or someone in your life is taking compounded semaglutide.
This post is a plain-language walkthrough of what compounded semaglutide actually is, how the telehealth compound market works, the specific safety and dosing issues, what the FDA is doing about it, and how to think about the transition.
What semaglutide actually is
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics a natural gut hormone that regulates appetite and blood glucose. When you take semaglutide, it binds to GLP-1 receptors in the pancreas (stimulating insulin release), the brain (reducing appetite and slowing gastric emptying), and various other tissues.
The clinical effects are substantial. In Type 2 diabetes patients, semaglutide reduces HbA1c by 1-2 percentage points. In weight-management use, average weight loss is 15% of body weight over 68 weeks in clinical trials. This is dramatically more effective than any prior pharmaceutical weight-loss intervention, and the drug has been transformative for hundreds of thousands of patients.
The branded semaglutide products are:
- Ozempic (subcutaneous injection, approved for Type 2 diabetes)
- Wegovy (subcutaneous injection, approved for chronic weight management in obesity)
- Rybelsus (oral tablet, approved for Type 2 diabetes)
All three are manufactured by Novo Nordisk. The compounded semaglutide market is separate from these products.
What compounded semaglutide actually is
Pharmaceutical compounding is the practice of preparing custom drug formulations for specific patients. Compounding pharmacies operate under two regulatory frameworks:
- 503A compounding pharmacies prepare drugs for individual patients based on a patient-specific prescription. Regulated primarily at the state level.
- 503B outsourcing facilities prepare drugs in larger volumes without patient-specific prescriptions, typically for hospitals and clinics. Regulated by the FDA.
Compounding pharmacies cannot generally produce drugs that are identical copies of FDA-approved commercial products. However, under Section 503A(a)(2) of the Federal Food, Drug, and Cosmetic Act, compounding of a drug that is on the FDA's official shortage list is permitted, even if a commercial version exists.
From 2022 to 2024, semaglutide was on the FDA shortage list. During that window, compounding pharmacies produced semaglutide for direct-to-patient distribution, largely through telehealth prescribing platforms. This was legal.
The compounded product was typically sold as "semaglutide with B12" or "semaglutide with L-carnitine" — a slight modification that arguably avoided being an "essentially copy" of the branded product. The compounding pharmacies used semaglutide active pharmaceutical ingredient (API) sourced from a handful of FDA-registered API manufacturers.
The specific risks in compounded semaglutide
1. API sourcing and quality
Not all API is created equal. Novo Nordisk manufactures its semaglutide API in Denmark under stringent process controls. Third-party API manufacturers vary in quality. Some produce excellent material at pharmaceutical purity. Others have had documented issues with impurities, sterility, and identity.
Independent testing of samples from various compounding pharmacies has found significant variation. Some compounded semaglutide is essentially identical to the branded product in purity. Some contains impurities at levels that would fail the branded product's release testing. Some contains lower-than-labeled amounts of active drug.
2. Compounding pharmacy quality
Compounding pharmacies themselves vary enormously in quality. 503B outsourcing facilities are inspected by the FDA. 503A pharmacies are regulated primarily by state boards and have inconsistent oversight. A small number of compounding pharmacies operating in the semaglutide space have received FDA warning letters for sterility violations, misbranding, or other quality issues.
The specific safety concern is injectable sterile products. Non-sterile injections can cause abscesses, systemic infection, and in extreme cases sepsis. Legitimate compounding pharmacies test for sterility on every lot. Some do not.
3. Dosing accuracy
Branded semaglutide comes in a pre-filled auto-injector pen with precisely calibrated dosing. Compounded semaglutide is often supplied as a multi-dose vial that the patient draws up with a syringe. This introduces dosing error at multiple points: reconstitution volume, syringe measurement, injection technique.
The therapeutic window for semaglutide is fairly wide, but dosing errors above the intended dose can cause severe GI side effects (nausea, vomiting, diarrhea), and in rare cases pancreatitis. Dosing errors below the intended dose result in inadequate clinical effect.
Semaglutide dosing is also complicated by the escalation schedule. The branded product uses a slow titration — starting at 0.25 mg weekly and increasing every 4 weeks to a maintenance dose of 1.7-2.4 mg. This schedule minimizes GI side effects. Compounded semaglutide protocols sometimes skip the escalation, which causes preventable side effects.
4. Substitution with unrelated compounds
The most serious sourcing risk. Some overseas suppliers labeled as "semaglutide" contain no semaglutide at all, or contain related but distinct GLP-1 agonists (like liraglutide) at different dosing. This is documented in independent testing of some suspect supply chains. Most reputable US compounding pharmacies are not sourcing from these suppliers, but the gray-market segment of the telehealth industry has been known to.
The FDA shortage resolution
In late 2024 and early 2025, the FDA declared the semaglutide shortage resolved. This has major implications:
- Compounding of semaglutide is no longer legally permitted under the shortage exemption.
- Compounding pharmacies producing semaglutide face increased FDA enforcement.
- Telehealth companies distributing compounded semaglutide need to transition patients to branded product or discontinue.
- Patients previously on compounded semaglutide need to make decisions about continuing.
The transition has been messy. Some telehealth companies have moved quickly to switch patients to branded product. Others continue to distribute compounded product using various legal theories (personalized formulation, custom adjustments) that may or may not survive FDA scrutiny. Some are shutting down or being investigated.
What the branded pathway costs
Novo Nordisk's list prices for Ozempic and Wegovy are approximately $900-$1,400 per month. Insurance coverage varies widely:
- Type 2 diabetes indication is generally covered under most insurance plans for Ozempic.
- Weight management indication (Wegovy) has been more restricted — many insurance plans do not cover it, though this is slowly improving.
- Medicare Part D does not currently cover weight-loss drugs, though this is legislatively contested.
Patient assistance programs from Novo Nordisk provide the branded product at reduced or zero cost for qualifying patients — typically those below certain income thresholds without insurance coverage. These programs are worth applying for.
For patients whose insurance does not cover the branded product and who cannot access patient assistance, the practical options after the shortage resolution are limited. Some patients travel to Canada, Mexico, or other countries where the branded product is cheaper. Others transition off semaglutide entirely.
The gray-market international purchasing option
Some patients have turned to international suppliers — primarily China-based API manufacturers or non-FDA-regulated markets — for semaglutide sold as "research chemicals" or through direct-to-consumer channels overseas. This is legally and safely worse than the compounded route.
The safety issues stack: unknown API quality, no sterility testing, no dosing standardization, and no regulatory recourse if something goes wrong. Independent testing of samples from Chinese peptide suppliers has repeatedly found significant variation in actual semaglutide content, purity, and endotoxin levels.
Patients taking this route are essentially self-experimenting with a hormone-modulating drug outside any regulatory framework. Some do fine. Some experience serious side effects. The population outcomes are not tracked because the population itself is invisible to health surveillance systems.
What's actually approved in 2026 (moving target)
The FDA-approved GLP-1 landscape as of 2026:
- Ozempic — semaglutide, Type 2 diabetes.
- Wegovy — semaglutide, chronic weight management.
- Rybelsus — oral semaglutide, Type 2 diabetes.
- Mounjaro — tirzepatide (dual GLP-1/GIP agonist), Type 2 diabetes. Eli Lilly.
- Zepbound — tirzepatide, chronic weight management.
- Trulicity — dulaglutide, Type 2 diabetes.
Tirzepatide is arguably more effective than semaglutide for weight management, and its supply chain has been more stable. If you have not yet started GLP-1 therapy and can access either, tirzepatide is worth discussing with your prescriber.
How to handle the transition responsibly
- If you're on compounded semaglutide from a legitimate US telehealth service, transition to branded product if possible. Work with your prescriber. The insurance landscape is improving.
- If cost is the barrier, apply for patient assistance. Novo Nordisk's programs and Eli Lilly's tirzepatide savings programs cover a significant portion of eligible patients.
- Do not switch to overseas gray-market sources. The safety math is significantly worse than compounded.
- Do not stop abruptly without medical guidance. Semaglutide is not physically addictive, but discontinuation causes weight regain in most patients. If you're going to stop, plan the maintenance strategy first.
- Understand this is a long-term therapy. Semaglutide and tirzepatide, in the current evidence base, are best understood as chronic medications rather than short-term interventions. Discontinuation typically results in regain over 12-24 months.
The bigger picture
The compounded semaglutide market emerged as a genuinely useful response to a real drug shortage. During 2022-2024, hundreds of thousands of patients accessed a life-changing medication at costs they could actually afford, and the outcome for those patients — on average — was significant weight loss and improved metabolic health.
The transition away from that market is going to be painful. Many patients will lose access to a medication that has been working for them. The insurance system is not yet catching up quickly enough to replace the compounding channel. This is a policy failure whose costs are being borne by patients.
What we can say from an evaluation standpoint: the branded pathway is safer, the gray-market international pathway is much less safe, and the compounding pathway is being wound down whether we approve or not. Vyvata's methodology page lays out how we evaluate pharmaceutical products (in short: we don't, because our catalog focuses on wearables, supplements, and devices rather than prescription drugs). But the same evaluation logic applies. Regulated manufacturing, verifiable quality control, sterile packaging, and legal recourse if something goes wrong are what you pay for when you buy the branded product.
Whatever you decide about semaglutide, decide it with clear eyes about the tradeoffs. This is not a category where the cheaper alternative is functionally equivalent to the expensive one. The prices reflect real quality differences in the underlying manufacturing chain, and those differences matter for a drug you inject weekly.
